Several studies have examined the use of PTEN loss as a biomarker in PC; one study suggested that patients exhibiting PTEN loss in Gleason score 6 tumours, identified from biopsy tissue, were at higher risk of having their score upgraded using samples obtained at RP [314]. This evidence concerns the gene PTEN and neoplasm.